PD-L1 tie-up shows Chinese pharma 'more competitive'

30 March 2020
china_credit_depositphotos_large

Jiangsu Alphamab Biopharmaceuticals has established strategic partnership with Simcere and 3D Medicines to advance the development and commercialization of a checkpoint inhibitor for programmed cell death ligand-1 (PD-L1), for oncology indications in mainland China.

The asset concerned is KN035, also known as envafolimab, a drug invented by Alphamab Oncology (HK: 9966), of which Jiangsu Alphamab is a wholly-owned subsidiary.

Advantages over other PD1/PD-L1 antibodies

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology